Trianni, Inc.

Picobella

Other

University of California

Austrianni Gmbh

Matthias Wabl

Bruce Wang

Werner Mueller

Bao Duong

Nigel Killeen

Jurgen Bachl

Gloria Esposito

Peter Burrows

Günther Adolf

Rolf Jessberger

Peter Daniel Burrows

The present invention comprises non-human vertebrate cells and non-human mammals having a genome comprising an introduced partially human immunoglobulin region, said introduced region comprising human Vcoding sequences and non-coding Vsequences based on the endogenous genome of the non-human mammal.

Transgenic animals and methods of use

The present invention relates to transgenic mammals that express canine-based immunoglobulins, including transgenic rodents that express canine-based immunoglobulins for the development of canine therapeutic antibodies.

Transgenic mammals and methods of use thereof

The invention relates to a long DH (LDH) cassette comprising a recombinant DH construct comprising at least two DH gene segments encoding at least 10 amino acids of the HCDR3 amino acid sequence, wherein at least one of the DH gene segments is a heterologous DH gene segment; an immunoglobulin heavy chain locus and a transgenic non-human animal comprising the same; and their use in producing an immunoglobulin library with long HCDR3 regions.

Long germline DH genes and long HCDR3 antibodies

The invention provides compositions and methods for enhanced production of immunoglobulin diversity. Specifically, the invention provides compositions and methods for making accessible a B cell receptor repertoire that has not been culled by developmental tolerance mechanisms. The invention also provides transgenic animals, cells, and antibodies resulting from these compositions and methods.

Enhanced immunoglobulin diversity

The present invention provides cells, transgenic animals, including transgenic mammals and particularly rodents comprising engineered immunoglobulin (Ig) alleles. Such engineered alleles, wherein an Ig light chain CL exon [C&#x3ba; or C&#x3bb; (C&#x3bb;1, C&#x3bb;2 or C&#x3bb;3)] is incorporated into the Ig heavy chain locus, are capable of producing heavy chain-only antibodies as a single chain VH antibody (scVHAb) or heavy chain antibody (HCAb) comprising two extended scVHAbs. The scVHAb comprises an antigen-binding part consisting of a VH domain and the immunoglobulin constant domains CL, which is either C&#x3ba; or C&#x3bb;, and CH1, in the order from N-terminus to C-terminus: VH-L1-CL-L2-CH1, wherein L1 and L2 are each, independently, peptidic linkers; and wherein CL is paired with CH1 through beta-sheet contact thereby obtaining a CL/CH1 dimer.

Single chain VH and heavy chain antibodies

The present invention relates to transgenic mammals that express bovine-based immunoglobulins, including transgenic rodents that express bovine-based immunoglobulins for the development of bovine therapeutic antibodies.

Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Methods for diagnosing and treating kidney cancer

Methods for diagnosing and treating prostate cancer are disclosed. In practicing the method, a subject's body-fluid sample is assayed for GPC3 protein, and the GPC3 level observed is used in determining whether the subject has an elevated GPC3 level associated with prostate cancer. Patients with such elevated levels may be treated, in accordance with the invention, with a variety of GPC3-related immunotherapy agents.

Methods for screening for prostate cancer

Methods, reagents and kits for diagnosing and treating cancer such as kidney or colorectal cancer are disclosed. An immunoassay for detecting kidney or colorectal cancer is based on the relative change of the ADAMTSL4 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney or colorectal cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Methods for diagnosing and treating kidney and colorectal cancer

The present invention provides isolated SRTA-70 proteins that mediate immunoglobulin class switch recombination in antibody-producing cells, and methods of procuding such proteins. The invention further provides isolated polynucleotides encoding SRTA-70 proteins, as well as vectors and host cells comprising the polynucleotides. The invention further provides methods of using SRTA-70 proteins to identify agents that modulate immunoglobulin class switch.

Polynucleotides encoding proteins mediating switch recombination

A method is provided for performing saturation mutagenesis on a target gene by exploiting the immunoglobulin hypermutation system. A target gene is cloned into an expression vector containing immunoglobulin enhancer fragments that effect hypermutation, and this construct is then transfected into an immunoglobulin mutator cell, typically of pre-B lymphocyte lineage. The target gene is permitted to hypermutate at a rate approaching that of 10.sup.-4 /bp/generation as the cells are cultured to a desired density. The variant polypeptides encoded by the hypermutated target gene can then be selected.

Growing community of inventors

San Francisco, CA, United States of America

Matthias Wabl